Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PANACEA LIFE SCIENCES HOLDINGS, INC.EXDI · Entity 9699 | Director | November 20, 2019 | November 22, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PANACEA LIFE SCIENCES HOLDINGS, INC.
Report date November 20, 2019 · Filed November 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,250 |
Reported balance
After 2019-11-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-11-20 · Grant · Acquired 100,000 · Balance 100,250 F1: Award of restricted common stock that vests equally over 24 months commencing the date of grant, subject to the reporting person's continued service as director. F2: Reflects adjustment for the 1:8 reverse split of common stock, effective February 25, 2019. |
| Common StockSEC Table I · non-derivative | Indirect237,500(2) shares held by VelocityHealth Capital; 187,500(2) shares held by Donegal Bio Ventures | 425,000 |
Reported balance
Holding disclosure · report date 2019-11-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 425,000 F2: Reflects adjustment for the 1:8 reverse split of common stock, effective February 25, 2019. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.20 · Expires 2029-01-11 | Direct | 250,000 |
Reported balance
Holding disclosure · report date 2019-11-20 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 250,000 F2: Reflects adjustment for the 1:8 reverse split of common stock, effective February 25, 2019. |
| Series B-2 Preferred StockSEC Table II · derivative / convertible security · Expires 2050-01-17 | IndirectHeld by VelocityHealth Capital | 168,000 |
Reported balance
Holding disclosure · report date 2019-11-20 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 168,000 F3: Shares of Series B-2 preferred stock are convertible into shares of common stock at a conversion rate of 0.125 shares of common stock for every 1 share of Series B-2 preferred stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of restricted common stock that vests equally over 24 months commencing the date of grant, subject to the reporting person's continued service as director.
F2: Reflects adjustment for the 1:8 reverse split of common stock, effective February 25, 2019.
F3: Shares of Series B-2 preferred stock are convertible into shares of common stock at a conversion rate of 0.125 shares of common stock for every 1 share of Series B-2 preferred stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2019 Filed Nov 22, 2019 18:00 UTC | PANACEA LIFE SCIENCES HOLDINGS, INC. EXDI · Entity 9699 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001388 · form4-11222019_031136.xml · nonDerivative · entry 1 ESVAL KEVIN JAMES · CIK 0001438014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,250 F1 · shares: Award of restricted common stock that vests equally over 24 months commencing the date of grant, subject to the reporting person's continued service as director. F2 · balance_after: Reflects adjustment for the 1:8 reverse split of common stock, effective February 25, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.